Core Viewpoint - Cogent Biosciences, Inc. has successfully closed an upsized underwritten public offering of 25,555,556 shares of common stock at a price of $9.00 per share, raising approximately $230 million in gross proceeds [1][2]. Group 1: Offering Details - The offering included 3,333,333 shares from the underwriters' option to purchase additional shares [1] - The net proceeds will be utilized for the development and commercial preparation of bezuclastinib and other product candidates, as well as for working capital and general corporate purposes [2]. - J.P. Morgan, Leerink Partners, and Guggenheim Securities served as joint book-running managers for the offering [2]. Group 2: Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with its leading clinical program being bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation [6]. - The company is also conducting a Phase 1 study of a novel FGFR2 inhibitor and is developing therapies targeting mutations in ErbB2, PI3Kα, and KRAS [6].

Core Viewpoint - Cogent Biosciences, Inc. has announced a public offering of 22,222,223 shares of common stock at a price of $9.00 per share, aiming to raise approximately $200 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 3,333,333 shares on the same terms [1]. - The expected closing date for the offering is around July 10, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for the development, regulatory, and commercial preparation activities related to bezuclastinib and other product candidates [2]. - Funds will also support the planned commercial launch of bezuclastinib, along with working capital and general corporate purposes [2]. Group 3: Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with bezuclastinib being the most advanced clinical program [5]. - Bezuclastinib is a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which is associated with systemic mastocytosis and advanced gastrointestinal stromal tumors [5]. - The company is also conducting a Phase 1 study of a novel FGFR2 inhibitor and developing therapies targeting mutations in ErbB2, PI3Kα, and KRAS [5].

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $150 million of its shares of common stock. In addition, Cogent intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its shares of common stock on the same terms and conditions. All o ...

Core Insights - Bezuclastinib has shown significant clinical benefits in treating patients with non-advanced systemic mastocytosis (NonAdvSM), achieving a statistically significant mean change in total symptom score (TSS) at 24 weeks compared to placebo [1][2][3] - The drug demonstrated a substantial reduction in serum tryptase levels, with 87.4% of patients experiencing at least a 50% reduction, contrasting with 0% in the placebo group [1][2] - Bezuclastinib is expected to submit a New Drug Application (NDA) to the FDA by the end of 2025, supported by a strong financial position with $237 million in cash and access to an additional $350 million [1][2][6] Clinical Trial Results - The SUMMIT trial achieved its primary endpoint with a mean reduction of 24.3 points in TSS for the bezuclastinib group versus 15.4 points for placebo, resulting in a placebo-adjusted improvement of 8.91 points (p=0.0002) [2][3] - All key secondary endpoints also showed statistically significant improvements, including a ≥50% reduction in serum tryptase (p<0.0001) and other measures of mast cell burden [3][4] Safety and Tolerability - Bezuclastinib exhibited a favorable safety profile, with the majority of treatment-emergent adverse events (TEAEs) being low grade; 98.3% in the bezuclastinib arm compared to 88.3% in the placebo arm [4][5] - Common TEAEs included hair color change (69.5% vs. 5.0% placebo), altered taste (23.7% vs. 0%), and nausea (22.0% vs. 13.3%) [4][5] Future Plans - Cogent plans to present detailed results from the SUMMIT trial at an upcoming medical meeting later this year and is on track to share pivotal trial results from the PEAK and APEX trials in the second half of 2025 [1][6][5]

WALTHAM, Mass. and BOULDER, Colo., May 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 7:35 a.m. ET. A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours afte ...

WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from four pipeline programs during poster sessions at the American Association for Cancer Research (AACR) 2025 Annual Meeting taking place in Chicago. “We welcome the opportunity to present updated results from these programs that represent our exciting pipeline of po ...